| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Dyne Therapeutics, Inc. (DYN) has 7 insiders with recent SEC Form 4 filings, including 2 buys and 0 sells. DYN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 5.28M | $110.10M | - | |
| Dir | 1.16M | $24.19M | - | |
| CEO | 368.2K | $7.68M | -2,683 | |
| Other | 169.2K | $3.53M | -887 | |
| Other | 154.2K | $3.22M | -145 |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 21, 2020 | Ra Capital Management, L.P.53 | 10% Owner | Buy | 660,000 | $19.00 | $12,540,000.00 | +30.8% | |
| Sep 21, 2020 | Logos Global Management LP | 10% Owner | Buy | 700,000 | $19.00 | $13,300,000.00 | +87.0% |